



(51) International Patent Classification:
A61M 31/00 (2006.01)

(21) International Application Number:
PCT/US2009/064465

(22) International Filing Date:
13 November 2009 (13.11.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/114,958 14 November 2008 (14.11.2008) US

(71) Applicant (for all designated States except US): **MIN-NOW MEDICAL, INC.** [US/US]; 10911 Technology Place, San Diego, California 92127 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PERRY, Mike** [US/US]; 10911 Technology Place, San Diego, California 92127 (US). **STONE, Corbett W.** [US/US]; 10911 Technology Place, San Diego, California 92127 (US). **GUSTUS, Rolfe Tyson** [US/US]; 10911 Technology Place, San Diego, California 92127 (US). **SCHREIBER, Ron-da** [US/US]; 10911 Technology Place, San Diego, California 92127 (US). **MAZOR, Meital** [IL/US]; 10911 Technology Place, San Diego, California 92127 (US). **CONN, Brian** [US/US]; 10911 Technology Place, San Diego, California 92127 (US).

(74) Agents: **BARRISH, Mark D.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, California 94111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SELECTIVE DRUG DELIVERY IN A LUMEN




FIG. 10

(57) Abstract: Methods and systems are disclosed for selective drug or fluid delivery in a lumen through a coating or fluid delivery channels. One system includes an elongate catheter having a proximal end and a distal end with an axis therebetween, the catheter having a radially expandable balloon near the distal end and an energy delivery portion proximate the balloon for transmission of energy, a thermally changeable coating having a releasable drug coupled to the balloon, the thermally changeable coating being oriented to be urged against the body tissue when the expandable balloon expands and an energy source operatively coupled to the energy delivery portion configured to energize the energy delivery portion to heat and liquefy the thermally changeable coating to release the drug to the body tissue.



SELECTIVE DRUG DELIVERY IN A LUMEN

CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] The present application claims the benefit under 35 USC 119(e) of US Provisional
5 Application No. 61/114,958 filed November 14, 2008; the full disclosure of which is
incorporated herein by reference in their entirety.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

10 [0002] NOT APPLICABLE

BACKGROUND OF THE INVENTION

[0003] The present invention is generally related to medical devices, systems, and methods. In
particular, the invention provides methods and systems for selective drug delivery to body tissue
15 disposed about a lumen using a catheter-based treatment system.

[0004] Physicians use catheters to gain access to and repair interior tissues of the body,
particularly within the lumens of the body such as blood vessels. For example, balloon
angioplasty and other catheters often are used to open arteries that have been narrowed due to
atherosclerotic disease. Balloon angioplasty is often effective at opening an occluded blood
20 vessel, but the trauma associated with balloon dilation can impose significant injury, so that the
benefits of balloon dilation may be limited in time.

[0005] Stenting, in conjunction with balloon dilation, is often the preferred treatment for
atherosclerosis. In stenting, a collapsed metal framework is mounted on a balloon catheter which
is introduced into the body. The stent is manipulated into the site of occlusion and expanded in
25 place by the dilation of the underlying balloon. Stenting has gained widespread acceptance, and
produces generally acceptable results in many cases. Along with treatment of blood vessels
(particularly the coronary arteries), stents can also be used in treating many other tubular
obstructions within the body, such as for treatment of reproductive, gastrointestinal, and

pulmonary obstructions. Restenosis or a subsequent narrowing of the body lumen after stenting has occurred in a significant number of cases.

[0006] A variety of modified restenosis treatments or restenosis-inhibiting treatment modalities have also been proposed, including intravascular radiation, cryogenic treatments, ultrasound energy, and the like, often in combination with balloon angioplasty and/or stenting. While these and different approaches show varying degrees of promise for decreasing the subsequent degradation in blood flow following angioplasty and stenting, the trauma initially imposed on the tissues by angioplasty remains problematic.

[0007] A number of alternatives to stenting and balloon angioplasty have been proposed to open stenosed arteries. For example, a wide variety of atherectomy devices and techniques have been disclosed and attempted. Despite the disadvantages and limitations of angioplasty and stenting, atherectomy has not gained the widespread use and success rates of dilation-based approaches. More recently, still further disadvantages of dilation have come to light. These include the existence of vulnerable plaque, which can rupture and release materials that may cause myocardial infarction or heart attack.

[0008] More recently, drug coated stents (such as Johnson and Johnson's Cypher stent, the associated drug comprising Sirolimus) have demonstrated a markedly reduced restenosis rate, and others are developing and commercializing alternative drug eluting stents. While drug eluting stents appear to offer significant promise for treatment of atherosclerosis in many patients, there remain many cases where stents either cannot be used or present significant disadvantages. Generally, stenting leaves an implant in the body. Such implants can present risks, including mechanical fatigue, corrosion, thrombus formation, and the like, particularly when removal of the implant is difficult and involves invasive surgery. Stenting may have additional disadvantages for treating diffuse artery disease, for treating bifurcations, for treating areas of the body susceptible to crush, and for treating arteries subject to torsion, elongation, and shortening.

[0009] In light of the above, it would be advantageous to provide methods and systems for selective fluid delivery to artery tissue that avoids the drawbacks associated with drug eluting stents and the devices described above.

BRIEF SUMMARY OF THE INVENTION

[0010] The present invention generally provides devices, systems, and methods for selective drug or fluid delivery to a body tissue being disposed about a lumen.

5 **[0011]** In a first aspect, the invention comprises a system for selective drug delivery to a body tissue being disposed about a lumen. The system includes an elongated flexible catheter body having a proximal end and a distal end with a radially expandable balloon near the distal end of the catheter body. An energy delivery surface disposed about the expandable balloon and a thermally changeable drug coating is coupled to the balloon, the energy delivery surface and the
10 thermally changeable coating being oriented to be urged against the body tissue when the expandable balloon expands. An energy source is operatively coupled to the energy delivery surface configured to energize the energy delivery surface to heat and liquefy the thermally changeable coating to release the drug to the body tissue.

[0012] In another aspect, the invention comprises a method for selective drug delivery in a
15 lumen. The method includes engaging a body tissue disposed about the lumen with an energy delivery surface and a thermally changeable coating having a releasable drug disposed on a radially expandable balloon near a distal end of a catheter when the expandable balloon expands, selectively energizing the energy delivery surface to heat and liquefy portions of the thermally changeable drug coating, and releasing a drug from the coating into the body tissue.

20 **[0013]** In many embodiments, the energy delivery surface comprises a plurality of electrodes, the energy source operatively coupled to the plurality of electrodes so as to selectively energize electrode pairs to heat and liquefy portions of the thermally changeable coating between the electrode pairs to release the drug to the body tissue. In many embodiments the body tissue of the lumen includes a diseased portion and select electrode pairs are energized to selectively heat
25 the thermally changeable coating proximate the diseased portion.

[0014] In many embodiments, the energy delivery surface comprises a plurality of electrodes disposed about the expandable balloon so as to define a plurality of remodeling zones in the tissue when the balloon is expanded within the lumen, the electrodes are radially coupled with the tissue, and energy is transmitted between the electrodes and the tissue.

[0015] In many embodiments, further comprising a tissue analyzer configured to characterize the body tissue.

[0016] In many embodiments, the energy delivery surface is energized to heat the thermally changeable coating to release the drug in responses to the characterized body tissue.

5 [0017] In many embodiments, the body tissue of the lumen includes a diseased portion and select electrode pairs are energized to selectively heat the thermally changeable coating proximate the diseased portion.

[0018] In many embodiments, the energy delivery surface is energized to heat the body tissue in combination with the drug delivery.

10 [0019] In many embodiments, the thermally changeable drug coating includes more than one drug

[0020] In many embodiments, the drug is selected from at least one of, a therapeutic fluid, an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic compound, an anti-thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically
15 conductive compound to lower the impedance at the electrode, an electrically insulating compound to prevent treatment to tissue that does not need treatment, an electrically conductive compound that is intended to migrate through the endothelial layers of tissue to carry energy to the interstitial layers, or a combination of the above.

[0021] In another aspect, the invention comprises a catheter system for drug delivery to a body
20 tissue being disposed about a lumen. The system includes an elongated flexible catheter body having a proximal end and a distal end, a radially expandable balloon near the distal end of the catheter body, and an energy delivery surface disposed about the expandable balloon. A plurality of biomolecules having a thermally releasable drug portion and an inert portion covalently bound to the balloon and an energy source operatively coupled to the energy delivery
25 surface so as to heat the biomolecules to release the drug portion to the body tissue.

[0022] In another aspect, the invention comprises a method for fluid delivery in a lumen. The method includes engaging a body tissue disposed about the lumen with an energy delivery surface and a plurality of biomolecules having a thermally releasable drug portion and an inert

portion covalently bound to the balloon near a distal end of a catheter when the expandable balloon expands, energizing the energy delivery surface to heat the biomolecules, and releasing the drug portion from the biomolecules into the body tissue.

[0023] In many embodiments, the energy delivery surface comprises a plurality of electrodes, the energy source operatively coupled to the plurality of electrodes so as to selectively energize electrode pairs to heat the biomolecules between the electrode pairs to release the drug portion to the body tissue.

[0024] In many embodiments, the body tissue of the lumen includes a diseased portion and select electrode pairs are energized to selectively heat the biomolecules proximate the to the diseased portion.

[0025] In many embodiments, the energy delivery surface and biomolecules are oriented to be urged against the body tissue when the expandable balloon expands.

[0026] In many embodiments, further comprising a tissue analyzer configured to characterize the body tissue and the energy delivery surface is energized to heat the biomolecules to release the drug portion in responses to the characterized body tissue..

[0027] In many embodiments, the energy delivery surface is further energized to heat the body tissue in combination with the drug delivery.

[0028] In many embodiments, the biomolecules include more than one releasable drug.

[0029] In many embodiments, the drug portion is selected from at least one of, a therapeutic fluid, an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic compound, an anti-thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically conductive compound to lower the impedance at the electrode, an electrically insulating compound to prevent treatment to tissue that does not need treatment, an electrically conductive compound that is intended to migrate through the endothelial layers of tissue to carry energy to the interstitial layers, or a combination of the above.

[0030] In another aspect, the invention comprises a catheter system for selective fluid delivery to a body tissue being disposed about a lumen. The system includes an elongated flexible catheter body having a proximal end and a distal end, a radially expandable structure near the

distal end of the catheter body, a plurality of fluid delivery channels oriented to be urged against the body tissue when the expandable structure expands, the fluid delivery channels being initially blocked with a thermally changeable material, and an energy source connector operatively coupled to the fluid delivery channels so as to heat and liquefy the thermally changeable material to selectively open one or more of the fluid delivery channels for fluid release.

[0031] In another aspect, the invention comprises a catheter system for selective fluid delivery to a body tissue being disposed about a lumen. The system includes an elongated flexible catheter body having a proximal end and a distal end, a radially expandable structure near the distal end of the catheter body, a plurality of fluid delivery channels oriented to be urged against the body tissue of the lumen when the expandable structure expands, the fluid delivery channels being initially closed, and a plurality of micro-electromechanical systems (MEMS) coupled to the fluid delivery channels to selectively open one or more fluid delivery channels and release a fluid in the lumen.

[0032] In another aspect, the invention comprises a method for selective fluid delivery in a lumen. The method includes engaging a body tissue disposed about the lumen with a plurality of fluid delivery channels on a radially expandable structure near a distal end of a catheter when the expandable structure expands, selectively opening one or more fluid delivery channels, and releasing a fluid from the select fluid delivery channels into the lumen.

[0033] In many embodiments, the plurality of fluid delivery channels protrude from the expandable structure to penetrate the body tissue of the lumen.

[0034] In many embodiments, further comprising a tissue analyzer configured to characterize the body tissue to identify body tissue to be treated and selectively opening or closing one or more fluid delivery channels in responses to the characterized body tissue to treat the identified body tissue.

[0035] In many embodiments, the fluid delivery channels can be selectively energized to selectively open one or more fluid delivery channels in responses to the characterized body tissue.

[0036] In many embodiments, the radially expandable structure comprises a balloon and the fluid delivery channels are mounted on a circumference of the balloon.

[0037] In many embodiments, the radially expandable structure comprises an expandable basket and the fluid delivery channels are mounted on a circumference of the basket.

[0038] In many embodiments, the body tissue of the lumen includes a diseased portion and select electrodes are energized to selectively open one or more fluid delivery channels proximate
5 the diseased portion.

[0039] In many embodiments, select electrodes are energized to heat the body tissue in conjunction with the release of the fluid in the lumen.

[0040] In many embodiments, selectively opening one or more fluid delivery channels comprises selectively energizing electrodes coupled to the select fluid delivery channels to heat
10 the select fluid delivery channels to liquefy a thermal material initially closing the fluid delivery channel.

[0041] In many embodiments, the fluid is selected from at least one of, ceramide, suramin, rapamycin, paclitaxel, sirolimus, zotarolimus, everolimus, a therapeutic fluid, an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic compound, an anti-thrombolytic agent,
15 a lubricant (to allow higher temperatures without sticking), an electrically conductive compound to lower the impedance at an electrode, an electrically insulating compound to prevent treatment to tissue that does not need treatment, an electrically conductive compound that is intended to migrate through the endothelial layers of tissue to carry energy to the interstitial layers, or a combination of the above.

[0042] In yet another aspect, the invention comprises a method for selective fluid delivery in a lumen. The method includes engaging a body tissue disposed about the lumen with a plurality of fluid delivery channels on a radially expandable structure near a distal end of a catheter when the expandable structure expands, the balloon material is a membrane of a fixed pore size, and adding energy or heat to the fluid adjacent to the balloon surface allows the specific molecules to
25 be passed through the membrane at the specific region for the specific time by virtue of the energy/heat source being switched on or off.

BRIEF DESCRIPTION OF THE DRAWINGS

[0043] FIG. 1 schematically illustrates one embodiment of a catheter system having a coating for selective drug delivery to a body tissue being disposed about a lumen.

5 [0044] FIG. 2 schematically illustrates one embodiment of an inflatable balloon for use in the catheter system of FIG. 1.

[0045] FIG. 3A schematically illustrates a cross-sectional view and 3B is an enlarged view of the balloon of FIG. 2.

[0046] FIGs. 4A and 4B schematically illustrates coatings covering the electrodes.

[0047] FIG. 5 schematically illustrates the used of aptamers in treating tissue.

10 [0048] FIG. 6 schematically illustrates placement of electrode pairs for use in bipolar energy treatment before, during, or after drug delivery.

[0049] FIG. 7 schematically illustrates another embodiment of a catheter system having fluid delivery channels for selective fluid delivery to a body tissue being disposed about a lumen.

15 [0050] FIG. 8A schematically illustrates a cross-section and FIG. 8B is an enlarged section of the balloon in FIG. 7 showing fluid delivery channels through the balloon coupled to electrodes mounted on a surface of the balloon.

[0051] FIGs. 9A and 9B schematically illustrate cross-sectional views showing tissue treatment using biomolecules having a thermally releasable active portion and an inert portion coupled by covalent bond to a balloon surface.

20 [0052] FIG. 10 schematically illustrates another embodiment of a balloon having a membrane for selective drug delivery to a body tissue being disposed about a lumen.

DETAILED DESCRIPTION OF THE INVENTION

25 [0053] Many therapies have been developed to replace or improve upon traditional balloon angioplasty and stents. The alternative devices described in the BACKGROUND OF THE INVENTION either cut, ablate, or vaporize diseased tissue in an artery. For example, laser devices vaporize plaque and flush it downstream. Atherectomy devices excise plaque and suck it

out of the body. Cutting balloons incise the artery wall, damaging the tissue. Even a simple angioplasty balloon does trauma to the tissue. It would be advantageous to provide treatments to body tissue that do not cut, ablate, or vaporize.

[0054] The present invention discloses systems and methods for selective delivery of a fluid to body tissue in a lumen, in particular, selective drug delivery in a lumen. Selective delivery may also control when and where the drug is delivered, and the amount of drug delivered.

[0055] While the disclosure focuses on drug delivery, such as , ceramide, suramin, rapamycin, paclitaxel, sirolimus, zotarolimus, everolimus, a drug (anesthetic or therapeutic), many other suitable fluids may be also be delivered to body tissue, for example, a therapeutic fluid, a small molecule, a gene therapeutic compound, an anti-thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically conductive compound to lower the impedance at the electrode, an electrically insulating compound to prevent treatment to tissue that does not need treatment, an electrically conductive compound that is intended to migrate through the endothelial layers of tissue to carry energy to the interstitial layers, or a combination of the above.

[0056] In some embodiments of the present invention, a drug is incorporated into a coating on a balloon catheter that is thermally released once inside the lumen to selectively treat the tissue. In other embodiments, a fluid or drug may be delivered through fluid delivery channels in a catheter system to selectively treat the tissue. In still other embodiments, multiple fluids or drugs may be delivered as part of a coating, through the fluid delivery channels, by thermal osmosis through a membrane, or any combination thereof.. In some embodiments the drug may be delivered at one tissue site, while other embodiments portions of the drug to different sites.

[0057] Some embodiments of the present invention use heating to release the drug coating. Other embodiments combine fluid or drug delivery with heating of the tissue before, during or after delivery to the tissue. Devices for heating artery tissue using RF, ultrasound, microwave and laser energies have been disclosed in co-pending U.S. Patent Application Nos. 11/975,474, 11/975,383, 11/122,263 and U.S. Provisional Application No. 61/099,155, the full disclosures of which are incorporated herein by reference.

Drug Delivery During An Angioplasty Procedure

[0058] Some embodiments of the present invention provide systems and methods for drug delivery in a lumen in combination with heating during an angioplasty procedure. While drugs are disclosed, proteins, cells and/or molecules may also be delivered (discussed below). The angioplasty procedure itself is the procedure that will open the lumen. The heating will cause softening and shrinking of a lesion, enabling the plaque to reshape easily around the balloon while avoiding stretching of the vessel thus avoiding injury to the vessel. The drug will be released during the angioplasty procedure and the heating process. Drug delivery treatment during an angioplasty procedure will be a combination of:

- Pressure - due to the balloon in order to open the lumen. The pressure may be standard angioplasty dilation pressures of 10-16 atmospheres or may be more gentle dilation pressures of 6 atmospheres or less, and possibly as low as 1 to 2 atmospheres.
- Heating - due to the RF energy in order to soften and shrink the lesion. Heating may also have other benefits related to the drug or drug delivery (discussed below).
- Drug/Protein/Cell/Molecule - which will be released during the procedure.

[0059] The Drug/Molecule/Protein/Cell element can be built of one component, or in combination of others such as:

1. Drugs: any molecule which will enable prevention or reduction of smooth muscle cell (SMC) proliferation and/or migration from the media to the intima, for example: ceramide, suramin, rapamycin and paclitaxel. The heating of the tissue may have a key role in helping deliver the drug into the lesion or tissue, and deeper into the media.

2. Proteins: proteins such as anti-inflammatory proteins, antibodies and other kinds of proteins which will enable the reduction and healing of the inflammation inside the lesion, or enable prevention or reduction of SMC proliferation and migration. We can also use protein that will induce cell apoptosis or oncosis. The heating may have a key role in activating these proteins during the treatment, and if heated quickly during the procedure, enabling the maximum time exposure of the tissue to the proteins. In order to make sure that the proteins will be activated during the procedure, one should take into account the half-life of a protein. The half-life of a protein is the time it takes before any half of the protein pool for that particular protein is left. for human proteins, it ranges from minutes to 80 hours. In order to use proteins eluting balloon, the balloon needs to be maintained in lower temperature ($< 0^{\circ}\text{C}$), so the proteins won't be ruined and destroyed. Several of the proteins that may be combined to a molecule named

Adenosine-5'-triphosphate (ATP). ATP is a multifunctional nucleotide that is important as a "molecular currency" of intracellular energy transfer. In one example, the balloon is covered with the protein and the electrodes are covered with ATP (or the opposite) and the protein will be released with the balloon inflation, and the ATP will be released when the energy will be emitted from the electrodes (or the opposite).

3. Cells: coating the balloon with cells such as endothelium, or any other type of cell which can migrate to the lesion during the procedure, where they will release proteins or antibodies to heal the inflammation or prevent SMC proliferation and migration. The heat in this case is also to activate the cells during the procedure.

4. Molecules or proteins that can be attached or become activated when attached to heat shock proteins (HSP). HSP are a group of proteins whose expression is increased when the cells are exposed to elevated temperatures or other stress. For example, HSP27 functions in smooth muscle cells (SMC) migration. In this case the RF energy and the heating will result in elevation of HSP27 inside the SMC, so we can use any drug/molecule or protein directly to the SMC by using anti-HSP27 antibody. The concept is to use the heat and the outcomes of the heat in order to use other molecules or proteins to bind, degrade, inhibit or activate other proteins or cells in the lesion and in the media, in order to prevent restenosis.

Drug Delivery Coatings

[0060] Fig. 1 shows one embodiment of a catheter system 10 having a releasable coating for selective drug delivery to a body tissue being disposed about a lumen. The catheter system 10 includes a balloon catheter 12 having a catheter body 14 with a proximal end 16 and a distal end 18. Catheter body 14 is flexible and defines a catheter axis 15, and may include one or more lumens, such as a guidewire lumen 22 and an inflation lumen 24. Catheter 12 includes an inflatable balloon 20 adjacent distal end 18 and a housing 29 adjacent proximal end 16. Housing 29 includes a first connector 26 in communication with guidewire lumen 22 and a second connector 28 in fluid communication with inflation lumen 24. Inflation lumen 24 extends between balloon 20 and second connector 28. Both first and second connectors 26, 28 may optionally comprise a standard connector, such as a Luer-Loc™ connector. A distal tip may include an integral tip valve to allow passage of guidewires, and the like.

[0061] Housing 29 also accommodates an electrical connector 38. Connector 38 includes a plurality of electrical connections, each electrically coupled to electrodes 34 via conductors 36. This allows electrodes 34 to be easily energized, the electrodes often being energized by a controller 40 and power source 42, such as RF energy. In one embodiment, electrical connector 38 is coupled to an RF generator via a controller 40, with controller 40 allowing energy to be selectively directed to electrodes 34. While RF energy is disclosed, other suitable energy sources may be used, such as microwave energy, ultrasound energy, or laser energy, each having energy delivery portions configured to deliver the desired energy. See copending U.S. Provisional Application No. 61/099,155, the full disclosures of which are incorporated herein by reference.

[0062] In some embodiments, controller 40 may include a processor or be coupled to a processor to control or record treatment. The processor will typically comprise computer hardware and/or software, often including one or more programmable processor unit running machine readable program instructions or code for implementing some or all of one or more of the methods described herein. The code will often be embodied in a tangible media such as a memory (optionally a read only memory, a random access memory, a non-volatile memory, or the like) and/or a recording media (such as a floppy disk, a hard drive, a CD, a DVD, a non-volatile solid-state memory card, or the like). The code and/or associated data and signals may also be transmitted to or from the processor via a network connection (such as a wireless network, an Ethernet, an internet, an intranet, or the like), and some or all of the code may also be transmitted between components of catheter system 10 and within processor via one or more bus, and appropriate standard or proprietary communications cards, connectors, cables, and the like will often be included in the processor. Processor will often be configured to perform the calculations and signal transmission steps described herein at least in part by programming the processor with the software code, which may be written as a single program, a series of separate subroutines or related programs, or the like. The processor may comprise standard or proprietary digital and/or analog signal processing hardware, software, and/or firmware, and will typically have sufficient processing power to perform the calculations described herein during treatment of the patient, the processor optionally comprising a personal computer, a notebook computer, a tablet computer, a proprietary processing unit, or a combination thereof. Standard or proprietary input devices (such as a mouse, keyboard, touchscreen, joystick, etc.) and output devices (such as a printer, speakers, display, etc.) associated with modern computer systems may also be

included, and processors having a plurality of processing units (or even separate computers) may be employed in a wide range of centralized or distributed data processing architectures.

[0063] Balloon 20 is illustrated in more detail in Fig. 2. Balloon 20 generally includes a proximal portion 30 coupled to inflation lumen 24 and a distal portion 32 coupled to guidewire lumen 22. Balloon 20 expands radially when inflated with a fluid or a gas. In some embodiments, the fluid or gas may be non-conductive and/or cooled. In some embodiments, balloon 20 may be a low pressure balloon pressurized to contact the artery tissue. In other embodiments, balloon 20 is an angioplasty balloon capable of higher pressure to both heat the artery tissue and expand the artery lumen. Balloon 20 may comprise a compliant or non-compliant balloon having helical folds to facilitate reconfiguring the balloon from a radially expanded, inflated configuration to a low profile configuration, particularly for removal after use.

[0064] Electrodes 34 are mounted on a surface of balloon 20, with associated conductors 36 extending proximally from the electrodes. Electrodes 34 may be arranged in many different patterns or arrays on balloon 20. The system may be used for monopolar or bipolar application of energy. For delivery of bipolar energy, adjacent electrodes are axially offset to allow bipolar energy to be directed between adjacent circumferential (axially offset) electrodes. In other embodiments, electrodes may be arranged in bands around the balloon to allow bipolar energy to be directed between adjacent distal and proximal electrodes.

[0065] A coating 35 is coupled to the balloon 20 and positioned between electrodes 34, such as shown in FIGs. 3A and 3B. Coating 35 includes a fluid or drug to be delivered to the targeted tissue. It is envisioned that the coating will be thermally activated and configured to be released from the balloon surface at a temperature above body temperature (greater than 37C). The idea is to have the energy delivery or heat, change the phase of a coating compound from a solid to a liquid, and releases the drug. This temperature increase involves activating electrodes 34 using RF energy. As the energy is increased, the coating 35 between the electrodes 34 is heated and released thermally to the local tissue 48. Coating 35 is durable or flexible such that it can be folded with the balloon 20 without separation or delamination. This mechanism could release small or large molecular drug or pharma product. The drug could be in a solid gel form.

[0066] In some embodiments, a second coating 35A may be used to cover electrodes 34, such as shown in FIG. 4A. Second coating 35A may be an insulating coating on the electrodes 34. The second coating 35A would be used when treating inside a metallic object in the lumen, such as a stent, because if the electrodes 34 come in contact with metal, they may short and the treatment will end. If the electrodes 34 are coated with a material with electrical properties such that the electrodes can not be shorted with metallic objects, the treatment can continue even when in contact with metal objects. This would allow catheter system 10 to treat inside objects like stents. Second coating 35A may also act to insulate electrodes 34 from tissue 48, shown in FIG. 4B, which stops/prohibits energy flow through tissue 48 and sends the energy through coating 35, heating only the coating 35 between the electrodes 34, releasing the drug to the tissue 48. The second coating 35A may also include a different drug than coating 35.

[0067] Many types of drugs may be included in the coatings. For example, the coating may include drugs currently used in drug eluting stents, such as sirolimus (used in the Cypher™ stent), paclitaxel (used in the Taxus™ stent), zotarolimus (used in the Endeavour™ stent) and everolimus (used in the Xience V™ stent).

[0068] Some embodiments of the present invention may include aptamers 52 coated to the balloon 20 using a substrate that breaks down readily when heated, such as when the RF energy source is activated. Aptamers can be engineered to bind very specifically to various molecular targets such as small molecules, proteins, nucleic acids, and even cells, tissues and organisms. The aptamers 52 could be synthesized to bind 54 with desired tissue 48 to be treated, such as plaque, within the lumen or artery.

[0069] While the catheter system 10 is not powered and the balloon 20 deflated, the coating 35 with aptamers 52 would remain on the balloon 20. Once the balloon 20 is inflated and the energy unit turned on, the coating is released and the aptamers 52 bind to the desired tissue, such as shown in FIG. 5. In some embodiments, aptamers 52 would be conjugated to a microscopic bead 56 that is highly receptive to the energy 58, such as RF energy, emitted by the catheter system 10. The beads 56 convert the RF energy to thermal energy directly and only to the tissue that the aptamers 52 is in contact with.

[0070] Aptamers are nucleic acids that bind to the surface of molecules in much the same way as antibodies. One importance difference between aptamers and antibodies is that aptamers can

be produced by chemical synthesis whereas antibodies are produced biologically, first animals, then in culture or an expression system. Another important difference is that aptamers are very stable and not sensitive to their surrounding environment, including temperature.

[0071] In some embodiments, coating 35 may include a chemical solvent that has plaque softening properties. Ether, chloroform, benzene, and acetone are known to be lipid solvents. Furthermore, amino acids, proteins, carbohydrates, and nucleic acids are largely insoluble in these solvents. If the solvent is used in conjunction with tissue heating, the tissue treatment may require less energy over a shorter time period, lessening the chance of damage to healthy tissue. If the tissue includes calcium deposits, the same process used to deliver lipid solvents to plaque could be used to deliver calcium solvents to calcification sites. Calcium is highly soluble in a variety of organic solvents. In both cases, the solvent would be coupled to the surface of the balloon with a coating that would break down either with the application of heat or RF energy, or as the balloon is inflated.

[0072] In some embodiments, the coating may incorporate more than one drug, agent, or fluid listed herein within the coating, each having different phase change temperatures. For example, an anesthetic could be administered at a lower melting temperature prior to a specific treatment of higher temperature where there may be a nerve in the general location. In some embodiments, two coatings of differing material may be used, such as by layering. For example, a first layer may include a first drug that attaches to the target tissue and act as a receptor to a second drug in a second layer. In some embodiments the coating is non-conductive to reduce or eliminate electrical shorts between electrodes.

[0073] In some embodiments, tissue signature could be used to identify treatment regions with the use of impedance measurements. Impedance measurements utilizing the radially spaced electrodes 34 within a lumen can be used to analyze tissue. Impedance measurements between pairs of adjacent electrodes (and/or between pairs of separated electrodes), may differ when the current path passes through diseased tissue, and when it passes through healthy tissues of the luminal wall. Hence, impedance measurements between the electrodes on either side of diseased tissue may indicate a lesion, while measurements between other pairs of adjacent electrodes indicate healthy tissue. Other characterization, such as intravascular ultrasound, optical coherence tomography, or the like may be used to identify regions to be treated.

[0074] Some embodiments described herein may be used to treat atherosclerotic disease by selective drug delivery in combination with "gentle heating" utilizing the "Q10 Rule" to further enhance the fluid or drug treatment. Under the Q10 Rule, it is well known that rates of biochemical reactions usually double when temperature is increased by 10°C.

- 5 [0075] As shown in FIG. 6, electrodes 34 are positioned circumferentially around the balloon 20. RF energy 43 is directed to electrodes adjacent pairs of electrodes 34A and 34C, or 34A and 34D, or any combination of 34A-34D, treating both the healthy tissue 45 and atherosclerotic material 48 within lumen 50. This arrangement creates an energy path 43 through the tissue that delivers energy or heat ("tissue remodeling energy") in particular treatment zones or segments to
- 10 the artery tissue between the electrode pairs ("remodeling zones") having a volume between the electrode pairs at a specific depth. Using different combinations of electrode pairs may reduce or eliminate gaps between the remodeling zones by using overlapping pairs. Using electrode pairs with bipolar energy may avoid some potential issues of the monopolar approach. Diseased artery tissue 48 has a higher electrical resistivity than healthy artery tissue. By using pairs of
- 15 electrodes 34A, 34B in a bipolar system, tissue remodeling energy will go through the healthy tissue, diseased tissue, or a combination of both healthy and diseased tissues between the electrode pairs in the remodeling zones. Any number of electrode pairs may be used in different patterns or arrays to create a number of remodeling zones. The controller may apply either constant power, constant current, or constant voltage, whichever has the most advantage.
- 20 [0076] The controller 40 may energize the electrodes with about 0.25 to 5 Watts average power for 1 to 180 seconds, or with about 4 to 45 Joules. Higher energy treatments are done at lower powers and longer durations, such as 0.5 Watts for 90 seconds or 0.25 Watts for 180 seconds. Most treatments in the 2 to 4 Watt range are performed in 1 to 4 seconds. Using a wider electrode spacing, it would be appropriate to scale up the power and duration of the
- 25 treatment, in which case the average power could be higher than 5 Watts, and the total energy could exceed 45 Joules. Likewise, using a shorter or smaller electrode pair would require scaling the average power down, and the total energy could be less than 4 Joules. The power and duration are calibrated to be less than enough to cause severe damage, and particularly less than enough to ablate diseased tissue 48 within a blood vessel.

[0077] In some embodiments the delivery of the drug and gentle heat may be accompanied by balloon angioplasty using gentle dilation to remodel the artery with dilation pressures which are at or significantly lower than standard, unheated angioplasty dilation pressures. Where balloon inflation pressures of 10-16 atmospheres may, for example, be appropriate for standard angioplasty dilation of a particular lesion, modified dilation treatments combined with appropriate electrical potentials (through flexible circuit electrodes on the balloon, electrodes deposited directly on the balloon structure, or the like) described herein may employ from 10-16 atmospheres or may be effected with pressures of 6 atmospheres or less, and possibly as low as 1 to 2 atmospheres. Such moderate dilations pressures may (or may not) be combined with one or more aspects of the tissue characterization, tuned energy, eccentric treatments, and other treatment aspects described herein for treatment of diseases of the peripheral vasculature.

Covalently Bound BioMolecules

[0078] Current endovascular therapies for preventing or permanently removing hyperplastic neointima are not completely efficacious. While removal of such tissue is achieved by multiple such therapies, regrowth of the tissue is a frequent occurrence, leading to restenosis and dysfunctional blood flow. Drug-eluting stents are able to inhibit the frequency of restenosis, but fall short of completely restoring vascular function, owing to the presence of a persistent implant; the stent.

[0079] More recently, drug clotting balloons have shown an even greater reduction in the frequency of restenosis than drug eluting stents and are removed after treatment, however, high pressure inflation is required to optimally deliver the anti-proliferation/anti-inflammatory biomolecules. The molecules may function to prevent restenosis by preventing inflammatory cell influx (chemo taxis), cell proliferation. The molecules may also function to stabilize the IEL matrix by providing structural support, thus "setting" the lumen diameter.

[0080] Figs. 9A and 9B show another embodiment of a catheter system 200 for drug delivery to a body tissue 248. The system 200 is similar to system 10 above, except the use of biomolecules 235 coupled to the balloon 20 instead of a coating. The biomolecules 235 include a thermally releasable active portion 235a and an inert portion 235b coupled by covalent bond to a balloon 20 surface. The active portion or molecule 235b is capable of treating the desired tissue 248, which may be enhanced with temperature or pressure. The inert portion 235a of the

biomolecule stays on the balloon. The embodiment described herein utilizes a radiofrequency endovascular balloon catheter that, upon low pressure inflation and energy delivery from the balloon to the atherosclerotic lesion, hyper-thermally releases the active portion of the biomolecule that is covalently bound to the balloon, thus, delivering the active portion of the molecule to the targeted tissue. The energy may also include ultrasound emitting energy. The active molecule 235b functions to prevent production of hyperplastic tissue by any means, including, but not limited to, cytostasis (prevention of mitosis), receptor maturation (i.e., those receptors at/on cells on the targeted tissue that are adhesive to/for a chemotactic to/for infiltrating cells that promote hyperplastic tissue formation.

[0081] The molecule's bioactive portion 235b is released from the intact biomolecule 235 by delivery of energy (such as from electrodes 34) that induces a local hyperthermia environment. The molecule is stable under the hyperthermia conditions. The molecule can prevent one or all of the following functions:

- cell proliferation:
- cell function:
- receptor-ligand binding:
- chemotaxis of inflammatory cells to the target tissue and
- migration of cells in the native artery strata to the diseased tissue.

[0082] The influx of the molecule 235b into the diseased tissue 48 is facilitated and/or hastened by the energy mediated hypothermia, i.e., cleavage from the intact biomolecule, migration into the diseased tissue, and residence in the diseased tissue by virtue of increased porosity are all accelerated by the hyperthermia.

This invention uniquely delivers a bioactive molecule into diseased tissue with:

- greater speed, by hypothermal acceleration:
- more completeness, by rendering the diseased tissue more receptive/porous to the molecule: and/or
- with no inactive segments of the biomolecule, i.e., no polymer, inactive protein sequence/segment, or co-factors required for activation left at the treatment site (the inactive segments stay on the balloon).

[0083] Clinical application and uses are designed to reduce plaque, inhibit restenosis in stented or not-stented site, and may be used as an adjunctive treatment to aggressive non-implantable endovascular procedures and stent implants.

Fluid Delivery Channels

5 [0084] Fig. 7 shows another embodiment of a catheter system 100 having fluid delivery channels for selective fluid delivery to a body tissue being disposed about a lumen. The catheter system 100 includes a balloon catheter 112 having a catheter body 114 with a proximal end 116 and a distal end 118. Catheter body 114 is flexible and defines a catheter axis 115, and may include one or more lumens, such as a guidewire lumen 122 and an inflation lumen 124.

10 Catheter 112 includes an inflatable balloon 120 adjacent distal end 118 and a housing 129 adjacent proximal end 116. Housing 129 includes a first connector 126 in communication with guidewire lumen 122 and a second connector 128 in fluid communication with inflation lumen 124. Inflation lumen 124 extends between balloon 120 and second connector 128. Both first and second connectors 126, 128 may optionally comprise a standard connector, such as a Luer-Loc™

15 connector. A distal tip may include an integral tip valve to allow passage of guidewires, and the like.

[0085] Housing 129 also accommodates an electrical connector 138. Connector 138 includes a plurality of electrical connections, each electrically coupled to electrodes 134 via conductors 136. This allows electrodes 134 to be easily energized, the electrodes often being energized by a

20 controller 140 and power source 142, such as RF energy, microwave energy, ultrasound energy, or other suitable energy sources. In one embodiment, electrical connector 138 is coupled to an RF generator via a controller 140, with controller 140 allowing energy to be selectively directed to electrodes 134 or electrode pairs. Controller 140 may include a processor or be coupled to a processor to control or record treatment.

25 [0086] FIG. 8A shows a cross-section of the balloon 120 and FIG. 8B is an enlarged section showing fluid delivery channels 160 through the balloon 120 coupled to electrodes 134 mounted on a surface of balloon 120. Electrodes 134 include associated conductors extending proximally from the electrodes. Electrodes 134 and fluid delivery channels 160 may be arranged in many different patterns or arrays on balloon 120. Fluid delivery channels 160 may be coupled to a

30 fluid reservoir or lumen 162 holding the fluid 152. In some embodiments, the inflation medium

may contain the fluid to be delivered. In some embodiments, the channels 160 thru balloon 120 may be filled with wax-like material 164 that can be expelled thermally in order to open the channel (or any other material that can be expelled). In other embodiments, electrodes 134 may open and close a flap to release the fluid.

5 [0087] The delivery channels 160 may protrude from the balloon surface such that they are capable of penetrating the body tissue of the lumen. In some embodiments, the electrodes may penetrate the body tissue.

[0088] The catheter system 100 may also include a tissue analyzer configured to characterize the body tissue. In some embodiments, electrodes 134 may be sensing electrodes, as discussed
10 above, that could help characterize the tissue to identify regions to be treated or not using electrical impedance tomography. Other characterization, such as intravascular ultrasound, optical coherence tomography, or the like may be used to identify regions to be treated. Electrodes 134 may be energized in response to the characterized body tissue

[0089] Some embodiments described herein may be used to treat atherosclerotic disease by
15 selective fluid delivery in combination with "gentle heating" to further enhance the fluid delivery or treatment, as discussed above.

[0090] Electrodes 134 may be selectively energized to open or close fluid delivery channels 160 to treat tissue. One method includes opening the fluid delivery channels 160 by selectively heating the electrodes (by Joule heating or other means, including inducing a heightened
20 temperature in the adjacent region, whereby heat transfer could heat the electrode(s)), such that a material 164, that would otherwise block the channel, is phase changed from solid to liquid. Another possible method may include the use of MEMS (micro-electro-mechanical-systems) to open and/or close channels 160 selectively.

[0091] In some embodiments, the fluid delivery channels may be vias through the electrodes
25 (perfused electrodes). The vias or small holes may be used to deliver a fluid to the artery tissue proximate the electrode. The holes may be less than 1 μm in diameter and may be made with a laser or ion beam. The holes may be made in the electrodes and balloon. In one example, electrode pads on a flexible circuit are designed with vias that are plated. The flexible circuit is mounted on a balloon and a laser or ion beam is used to create the holes in the flexible substrate

and balloon. There may be several holes in the flexible/balloon for every electrode pad. The balloon may then be perfused with standard perfusion balloon equipment or specialized equipment. This perfusion approach may also provide additional advantages beyond fluid delivery, such as eliminating sticking, carry away heat or regulate the impedance of the load.

5 [0092] In some embodiments, a porous balloon may be used having fluid delivery channels on a micro-level, allowing select molecules through with the addition of heat. The porous balloon may have an inner layer, a porous outer layer or membrane, drug or fluid molecules positioned between the layers (i.e., a reservoir) and electrodes coupled to the outer layer. At low pressures, the molecules stay within the reservoir. As heat is applied, the molecules may go through the
10 porous layer, which may be done in different ways. For example, as the heat is applied, the drug molecules may become excited, providing enough force to go through the porous outer layer. In another example, as heat is applied to the balloon, the pores expand, allowing the drug molecules to go through the porous outer layer. The molecules may also pass through the porous outer layer or membrane by osmotic pressure along with the heat.

15 [0093] In some embodiments, the treatments may include a drug, and/or thermal, and/or small or large molecules injection, and/or RF, and/or balloon dilatation, and/or hyperthermia.

[0094] While the devices, systems, and methods disclosed herein discuss a balloon as the radially expandable structure, other expandable structures may also be used, such as described in U.S. Patent Application Nos. 11/975,651, the full disclosure of which is incorporated herein by
20 reference.

Thermally Excited Osmolarity

[0095] In some embodiments, a porous balloon may be used having fluid delivery channels on a micro-level in a membrane, allowing molecules through with the addition of pressure and heat. The concept delivers a fluid or drug to a specific site by passing it through the membrane, much
25 like reverse osmosis. In reverse osmosis, a pressure is used to drive a liquid, such as water, through a membrane with passages so small that only the appropriate molecules can pass through. In this embodiment, the membrane barrier retains a drug, like paclitaxel. At low pressures, the drug molecules are not able to pass through the membrane. To release the drug through the membrane, pressure is applied to the drug molecules using a balloon the release of

the drug is the accelerated by applying energy locally by an electrode pair or monopolar electrode.

[0096] FIG. 10 shows one embodiment of a catheter system, similar to catheter system 10, having a balloon 300 with a non-porous inner balloon 305 (to provide pressure), a porous outer layer, membrane or sleeve 310, a drug or fluid 315 positioned between inner balloon 305 and membrane 310 (i.e., a reservoir), and electrodes 320 coupled to the membrane 310. Electrodes 320 may be similar to the electrodes describe above.

[0097] In use, the balloon is placed at the desired tissue site and the balloon is inflated to a suitable pressure, such as 4-6 ATM. When the electrodes are energized, the heat energy causes the membrane pores to open and the drug molecule to excite and make their way through the pores to the tissue.

[0098] The devices, systems, and methods disclosed herein may be used to selectively deliver fluid in any artery, for example, the femoral, popliteal, coronary and/or carotid arteries. While the disclosure focuses on the use of the technology in the vasculature, the technology would also be useful for any luminal obstruction. Other anatomical structures in which the present invention may be used are the esophagus, the oral cavity, the nasopharyngeal cavity, the auditory tube and tympanic cavity, the sinus of the brain, the arterial system, the venous system, the heart, the larynx, the trachea, the bronchus, the stomach, the duodenum, the ileum, the colon, the rectum, the bladder, the ureter, the ejaculatory duct, the vas deferens, the urethra, the uterine cavity, the vaginal canal, and the cervical canal.

[0099] The devices, systems, and method disclosed herein may employ one or more of a wide variety of mechanisms to facilitate, promote, and/or enhance transport of at least one drug from a fluid, gel, or solid of a catheter (or other delivery structure) toward, to and/or into a desired treatment site or tissue. Exemplary thermally-mediated drug transport mechanisms which may be employed are described above. Additional mechanisms may also be used including electrically mediated drug transport mechanisms, optionally including mechanisms such as electroporation, iontophoresis, and the like. Electroporation may allow targeting drug molecules intracellularly via creating passages in the cell membrane. Electroporation can significantly increase the electrical conductivity and permeability of the cell plasma membrane by application of an external electrical field, optionally by application of an electroporation voltage (which may

involve a series of electroporation potentials) using one or more electrodes of the balloon catheters described herein. Iontophoresis may be employed by applying a relatively small electric potential so as to deliver a medicine or other chemical through the luminal surface, with the electrical potential again optionally being applied using one or more electrodes of the balloon catheters described hereinabove. As another example, anti-inflammatory molecules could be delivered via iontophoretic membranes to atherosclerotic lesions. Small molecule inhibitors of inflammation, thrombogenesis, and thrombosis can be delivered to atherosclerotic lesions via iontophoretic methods using devices and systems described herein to slow or prevent progression of atherosclerosis and thrombus formation. Examples of suitable inflammatory and/or thrombogenic tissue targets in the artery may include platelet cell adhesion factor (PECAM), Tissue Factor (TF), matrix metalloproteinases (MMP), and/or the like. Examples of a small molecule anti-inflammatory / anti-thrombosis therapeutics that would be amenable to delivery via iontophoresis may include heparin, heparin sulfate, and/or the like. Advantageously, suitable potentials may be applied in either a bipolar arrangement (between electrodes of the balloon catheter) or in a monopolar mode. Suitable potentials may be applied by commercially available iontophoresis or electroporation systems, or specialized potential generators may be employed. These drug transport mechanisms can optionally be combined, for example, with a thermal mechanism used (for example, by energizing electrodes so as to heat a coating, and optionally to facilitate release of a drug and thermally enhance movement of the drug into a target tissue), followed with an electrically mediated drug transport mechanism (optionally by energizing the same electrodes or different electrodes of the balloon with a suitable potential).

[0100] While the exemplary embodiments have been described in some detail, by way of example and for clarity of understanding, those of skill in the art will recognize that a variety of modification, adaptations, and changes may be employed. Hence, the scope of the present invention should be limited solely by the appending claims.

WHAT IS CLAIMED IS:

1 1. A catheter system for selective drug delivery to a body tissue being
2 disposed about a lumen, the system comprising:
3 an elongate catheter having a proximal end and a distal end with an axis
4 therebetween, the catheter having a radially expandable balloon near the distal end and an energy
5 delivery portion proximate the balloon for transmission of energy;
6 a thermally changeable coating having a releasable drug coupled to the balloon,
7 the thermally changeable coating being oriented to be urged against the body tissue when the
8 expandable balloon expands; and
9 an energy source operatively coupled to the energy delivery portion configured to
10 energize the energy delivery portion to heat and liquefy the thermally changeable coating to
11 release the drug to the body tissue.

1 2. The system of claim 1, wherein the energy delivery portion comprises a
2 plurality of electrodes disposed about the expandable balloon, the energy source operatively
3 coupled to the plurality of electrodes so as to selectively energize electrode pairs to heat and
4 liquefy portions of the thermally changeable coating between the electrode pairs to release the
5 drug to the body tissue.

1 3. The system of claim 2, wherein the body tissue of the lumen includes a
2 diseased portion and select electrode pairs are energized to selectively heat the thermally
3 changeable coating proximate the diseased portion.

1 4. The system of claim 1, wherein the energy delivery portion comprises a
2 plurality of electrodes disposed about the expandable balloon so as to define a plurality of
3 remodeling zones in the tissue when the balloon is expanded within the lumen, the electrodes are
4 radially coupled with the tissue, and energy is transmitted between the electrodes and the tissue.

1 5. The system of claim 1, further comprising a tissue analyzer configured to
2 characterize the body tissue.

1 6. The system of claim 5, wherein the energy delivery portion is energized to
2 heat the thermally changeable coating to release the drug in responses to the characterized body
3 tissue.

1 7. The system of claim 1, wherein the energy delivery portion is energized to
2 heat the body tissue before, during and/or after the drug delivery.

1 8. The system of claim 1, wherein the thermally changeable coating includes
2 more than one releasable drug.

1 9. The system of claim 1, wherein the drug is selected from at least one of,
2 ceramide, suramin, rapamycin, paclitaxel, sirolimus, zotarolimus, everolimus, a therapeutic fluid,
3 an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic compound, an anti-
4 thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically
5 conductive compound to lower the impedance at an electrode, an electrically insulating
6 compound to prevent treatment to tissue that does not need treatment, an electrically conductive
7 compound that is intended to migrate through the endothelial layers of tissue to carry energy to
8 the interstitial layers, or a combination of the above.

1 10. The system of claim 1, wherein the energy source is a RF energy source
2 and the energy delivery portion is configured to transmit RF energy.

1 11. The system of claim 1, wherein the energy source is a laser energy source
2 and the energy delivery portion is configured to transmit laser energy.

1 12. The system of claim 1, wherein the energy source is an ultrasound energy
2 source and the energy delivery portion is configured to transmit ultrasound energy.

1 13. The system of claim 1, wherein the energy source is a microwave energy
2 source and the energy delivery portion is configured to transmit microwave energy.

1 14. A method for selective drug delivery in a lumen, the method comprising:

2 engaging a body tissue disposed about the lumen with a thermally changeable
3 coating having a releasable drug disposed on a radially expandable balloon near a distal end of a
4 catheter when the expandable balloon expands;
5 selectively energizing an energy delivery portion of the catheter proximate the
6 balloon to heat and liquefy portions of the thermally changeable drug coating; and
7 releasing the drug from the thermally changeable coating into the body tissue.

1 15. The method of claim 14, wherein the energy delivery portion comprises a
2 plurality of electrodes disposed about the expandable balloon and select electrode pairs are
3 energized to heat and liquefy portions of the thermally changeable drug coating between the
4 electrode pairs.

1 16. The method of claim 15, wherein the body tissue of the lumen includes a
2 diseased portion and select electrode pairs are energized to heat the thermally changeable coating
3 proximate the diseased portion.

1 17. The method of claim 14, further comprising characterizing the body tissue
2 to identify body tissue to be treated and selectively heating portions of the thermally changeable
3 coating to release the drug in response to the characterized body tissue to treat the identified
4 body tissue.

1 18. The method of claim 14, further comprising heating the body tissue
2 before, during and/or after the drug delivery.

1 19. The method of claim 14, wherein the drug is selected from at least one of,
2 ceramide, suramin, rapamycin, paclitaxel, sirolimus, zotarolimus, everolimus, a therapeutic fluid,
3 an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic compound, an anti-
4 thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically
5 conductive compound to lower the impedance at an electrode, an electrically insulating
6 compound to prevent treatment to tissue that does not need treatment, an electrically conductive
7 compound that is intended to migrate through the endothelial layers of tissue to carry energy to
8 the interstitial layers, or a combination of the above.

1 20. The method of claim 14, wherein the energy delivery portion is energized
2 with RF energy.

1 21. The method of claim 14, wherein the energy delivery portion is energized
2 with laser energy.

1 22. The method of claim 14, wherein the energy delivery portion is energized
2 with ultrasound energy.

1 23. The method of claim 14, wherein the energy delivery portion is energized
2 with microwave energy.

1 24. A catheter system for drug delivery to a body tissue being disposed about
2 a lumen, the system comprising:
3 an elongate catheter having a proximal end and a distal end with an axis
4 therebetween, the catheter having a radially expandable balloon near the distal end and an energy
5 delivery portion proximate the balloon for transmission of energy;
6 a plurality of biomolecules having a thermally releasable drug portion and an inert
7 portion covalently bound to the balloon; and
8 an energy source operatively coupled to the energy delivery portion so as to heat
9 the biomolecules to release the drug portion to the body tissue.

1 25. The system of claim 24, wherein the energy delivery portion comprises a
2 plurality of electrodes disposed about the expandable balloon, the energy source operatively
3 coupled to the plurality of electrodes so as to selectively energize electrode pairs to heat the
4 biomolecules between the electrode pairs to release the drug portion to the body tissue.

1 26. The system of claim 25, wherein the body tissue of the lumen includes a
2 diseased portion and select electrode pairs are energized to selectively heat the biomolecules
3 proximate the diseased portion.

1 27. The system of claim 24, wherein the biomolecules are oriented to be urged
2 against the body tissue when the expandable balloon expands.

1 28. The system of claim 24, further comprising a tissue analyzer configured to
2 characterize the body tissue.

1 29. The system of claim 28, wherein the energy delivery portion is energized
2 to heat the biomolecules to release the drug portion in responses to the characterized body tissue.

1 30 . The system of claim 24, wherein the energy delivery portion is energized
2 to heat the body tissue before, during and/or after the drug delivery.

1 31. The system of claim 24, wherein the biomolecules include more than one
2 releasable drug.

1 32. The system of claim 24, wherein the drug portion is selected from at least
2 one of, ceramide, suramin, rapamycin, paclitaxel, sirolimus, zotarolimus, everolimus, a
3 therapeutic fluid, an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic
4 compound, an anti-thrombolytic agent, a lubricant (to allow higher temperatures without
5 sticking), an electrically conductive compound to lower the impedance at an electrode, an
6 electrically insulating compound to prevent treatment to tissue that does not need treatment, an
7 electrically conductive compound that is intended to migrate through the endothelial layers of
8 tissue to carry energy to the interstitial layers, or a combination of the above.

1 33. A method for drug delivery in a lumen, the method comprising:
2 engaging a body tissue disposed about the lumen with a plurality of biomolecules
3 having a thermally releasable drug portion and an inert portion covalently bound to the balloon
4 near a distal end of a catheter when the expandable balloon expands;
5 energizing an energy delivery portion of the catheter proximate the balloon to heat
6 the biomolecules; and
7 releasing the drug portion from the biomolecules into the body tissue.

1 34 . The method of claim 33, further comprising heating the body tissue
2 before, during and/or after the drug delivery.

1 35. The method of claim 33, wherein the energy delivery portion comprises a
2 plurality of electrodes disposed about the expandable balloon and select electrode pairs are

energized to heat the biomolecules between the electrode pairs to release the drug portion to the body tissue.

36. The method of claim 33, further comprising characterizing the body tissue to identify body tissue to be treated and selectively heating biomolecules to release the drug portion in response to the characterized body tissue to treat the identified body tissue.

37. A catheter system for selective fluid delivery to a body tissue being disposed about a lumen, the system comprising:
an elongated flexible catheter body having a proximal end and a distal end;
a radially expandable structure near the distal end of the catheter body;
a plurality of fluid delivery channels oriented to be urged against the body tissue when the expandable structure expands, the fluid delivery channels being initially blocked with a thermally changeable material; and
an energy source connector operatively coupled to the fluid delivery channels so as to heat and liquefy the thermally changeable material to selectively open one or more of the fluid delivery channels for fluid release.

38. The system of claim 37, wherein the plurality of fluid delivery channels protrude from the expandable structure to penetrate the body tissue of the lumen.

39. The system of claim 37, further comprising a tissue analyzer configured to characterize the body tissue.

40. The system of claim 39, wherein the fluid delivery channels can be selectively energized to selectively open one or more fluid delivery channels in responses to the characterized body tissue.

41. The system of claim 37, wherein the radially expandable structure comprises a balloon and the fluid delivery channels are mounted on a circumference of the balloon.

1 42. The system of claim 37, wherein the radially expandable structure
2 comprises an expandable basket and the fluid delivery channels are mounted on a circumference
3 of the basket.

1 43. The system of claim 37, wherein the body tissue of the lumen includes a
2 diseased portion and select electrodes are energized to selectively open one or more fluid
3 delivery channels proximate the diseased portion.

1 44 . The system of claim 37, wherein select electrodes are energized to heat the
2 body tissue in conjunction with the release of the fluid in the lumen.

1 45. The system of claim 37, wherein the fluid is selected from at least one of,
2 ceramide, suramin, rapamycin, paclitaxel, sirolimus, zotarolimus, everolimus, a therapeutic fluid,
3 an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic compound, an anti-
4 thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically
5 conductive compound to lower the impedance at an electrode, an electrically insulating
6 compound to prevent treatment to tissue that does not need treatment, an electrically conductive
7 compound that is intended to migrate through the endothelial layers of tissue to carry energy to
8 the interstitial layers, or a combination of the above.

1 46. A catheter system for selective fluid delivery to body tissue being
2 disposed about a lumen, the system comprising:
3 an elongated flexible catheter body having a proximal end and a distal end;
4 a radially expandable structure near the distal end of the catheter body;
5 a plurality of fluid delivery channels oriented to be urged against the body tissue
6 of the lumen when the expandable structure expands, the fluid delivery channels being initially
7 closed; and
8 a plurality of micro-electromechanical systems (MEMS) coupled to the fluid
9 delivery channels to selectively open one or more fluid delivery channels and release a fluid in
10 the lumen.

1 47. The system of claim 46, wherein the fluid is selected from at least one of,
2 ceramide, suramin, rapamycin, paclitaxel, sirolimus, zotarolimus, everolimus, a therapeutic fluid,

3 an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic compound, an anti-
4 thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically
5 conductive compound to lower the impedance at an electrode, an electrically insulating
6 compound to prevent treatment to tissue that does not need treatment, an electrically conductive
7 compound that is intended to migrate through the endothelial layers of tissue to carry energy to
8 the interstitial layers, or a combination of the above.

1 48. A method for selective fluid delivery in a lumen, the method comprising:
2 engaging a body tissue disposed about the lumen with a plurality of fluid delivery
3 channels on a radially expandable structure near a distal end of a catheter when the expandable
4 structure expands;
5 selectively opening one or more fluid delivery channels; and
6 releasing a fluid from the select fluid delivery channels into the lumen.

1 49. The method of claim 48, wherein selectively opening one or more fluid
2 delivery channels comprises selectively energizing electrodes coupled to the select fluid delivery
3 channels to heat the select fluid delivery channels to liquefy a thermal material initially closing
4 the fluid delivery channel.

1 50. The method of claim 48, wherein selectively open one or more fluid
2 delivery channels comprises a plurality of micro-electromechanical systems (MEMS) coupled to
3 the fluid delivery channels to selectively open and/or close the fluid delivery channels.

1 51. The method of claim 48, further comprising characterizing the body tissue
2 to identify body tissue to be treated and selectively opening or closing one or more fluid delivery
3 channels in responses to the characterized body tissue to treat the identified body tissue.

1 52. The method of claim 48, wherein the plurality of fluid delivery channels
2 are configured to penetrate into the lumen wall.

1 53. The method of claim 48, wherein the radially expandable structure
2 comprises a balloon and the fluid delivery channels are mounted on a circumference of the
3 balloon.

1 54. The method of claim 48, wherein the radially expandable structure
2 comprises an expandable basket and the fluid delivery channels are mounted on a circumference
3 of the basket.

1 55. The method of claim 48, further comprising heating the body tissue in
2 conjunction with releasing the fluid.

1 56. The method of claim 48, wherein the fluid is selected from at least one of,
2 ceramide, suramin, rapamycin, paclitaxel, sirolimus, zotarolimus, everolimus, a therapeutic fluid,
3 an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic compound, an anti-
4 thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically
5 conductive compound to lower the impedance at an electrode, an electrically insulating
6 compound to prevent treatment to tissue that does not need treatment, an electrically conductive
7 compound that is intended to migrate through the endothelial layers of tissue to carry energy to
8 the interstitial layers, or a combination of the above.

1 57. A catheter assembly for use with an energy source for drug delivery to a
2 body tissue being disposed about a lumen, the assembly comprising:

3 an elongate catheter having a proximal end and a distal end with an axis
4 therebetween, the proximal end of the catheter coupleable to the energy source and the catheter
5 having a radially expandable balloon near the distal end with an energy delivery portion
6 proximate the balloon for transmission of energy from the energy source;

7 a drug; and

8 a thermally-activated material releasably restraining the drug along the balloon in
9 an insertion configuration, the material thermally reconfigurable in response to the energy when
10 the balloon is expanded within the lumen so as to deliver the drug from the balloon to the body
11 tissue.





1 58. The catheter assembly of claim 57, wherein the thermally-activated
2 material comprises at least one member selected from the group consisting of:

3 a thermally changeable coating material, the coating material and drug forming a
4 coating disposed on the balloon in the insertion configuration;

5 at least one inert biomolecule bonding the drug to the balloon in the insertion
6 configuration; and
7 at least one micro-electromechanical system operatively coupled to at least one
8 associated fluid delivery channel having the drug therein so as to restrain the drug in the insertion
9 configuration.

1 59. A catheter system for selective drug delivery to a body tissue being
2 disposed about a lumen, the system comprising:
3 an elongated flexible catheter body having a proximal end and a distal end;
4 a radially expandable balloon near the distal end of the catheter body containing a
5 drug, the balloon having a thermally changeable porous surface being oriented to be urged
6 against the body tissue when the expandable balloon expands, the initial size of the pores of the
7 porous surface sized not allowing passage of the drug; and
8 an energy delivery portion couple to the porous surface the balloon for
9 transmission of energy so as to heat thermally changeable porous surface to increase the size of
10 the pores to pass the drug from the balloon to the body tissue.

1 / 4



2 / 4




FIG. 4A




FIG. 4B




FIG. 5







FIG. 6






FIG. 9A




FIG. 9B




FIG. 10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2009/064465

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61M 31/00 (2010.01)

USPC - 604/103.01

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61M 31/00 (2010.01)

USPC - 604/101.04, 103.01, 103.02, 103.05, 103.06, 103.08, 103.09, 103.11; 606/27,32; 600/381

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MicroPatent

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,304,121 A (SAHATJIAN) 19 April 1994 (19.04.1994) entire document	1, 4, 9, 14, 17, 19, 24-27, 32, 33,35, 36, 46-48, 50-53, 56-59
Y		2, 3, 5-8,10-13,15, 16, 18, 20-23, 28-31, 34, 37-45, 49, 54, 55
Y	US 2004/0062852 A1 (SCHROEDER et al) 01 April 2004 (01.04.2004) entire document	2, 3, 15, 16, 37-44, 45, 49
Y	US 2005/0283195 A1 (PASTORE et al) 22 December 2005 (22.12.2005) entire document	5, 6, 28, 29, 39, 40
Y	US 2006/0235286 A1 (STONE et al) 19 October 2006 (19.10.2006) entire document	7, 10, 13, 18, 20, 23, 30, 34, 44, 55
Y	US 2007/0278103 A1 (HOERR et al) 06 December 2007 (06.12.2007) entire document	8, 31
Y	US 6,706,011 B1 (MURPHY-CHUTORIAN et al) 16 March 2004 (16.03.2004) entire document	11, 21
Y	US 6,723,064 B2 (BABAEV) 20 April 2004 (20.04.2004) entire document	12, 22
Y	US 5,306,250 A (MARCH et al) 26 April 1994 (26.04.1994) entire document	42, 54

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

04 January 2010

Date of mailing of the international search report

13 JAN 2010

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774